ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1128

Physician-Patient Interaction and Medication Adherence in Lupus Nephritis

Sofia Georgopoulou1, Louise Nel 2, Shirish Sangle 2 and David D'Cruz 3, 1King's College London & The Royal Marsden Hospital NHS Foundation Trust, London, England, United Kingdom, 2Guy's & St Thomas' Hospitals NHS Foundation Trust, London, England, United Kingdom, 3The Louise Coote Lupus Unit, Guy's Hospital, London, England, United Kingdom

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Lupus nephritis, medication adherence, Physician-Patient Interaction, Trust and Illness Perceptions

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: Health Services Research Poster II – ACR/ARP

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: The quality of physician-patient interaction can have a significant impact on medication adherence. Little is known about this relationship in patients with lupus nephritis (LN).

Methods: Cross-sectional, quantitative study. Data collected included demographics, current medication, SLEDAI, medication adherence, beliefs about medicines, shared decision-making (SDM), patient-doctor depth of relationship (PDDR); patient-doctor quality of relationship (PRDQ9), interpersonal trust in a physician (ITP), and illness perceptions.

Results: 98 patients satisfying the American College of Rheumatology (ACR) classification criteria for LN completed the questionnaires. Binary logistic regression indicated that medication adherence was significantly predicted by: (a) ITP (B= 0.85; Wald= 3.94; 95%CI: 1.01, 5.44; p=0.05); (b) timeline cyclical (B= -0.89; Wald= 4.95; 95%CI: 0.19, 0.90 p< 0.05) and beliefs about necessity of medicines (B= 0.75; Wald= 4.14; 95%CI: 1.03, 4.38; p< 0.05). Mediation analysis showed that BMQ_N significantly mediated the relationship between trust and medication adherence when adjusted for age (B= 0.48, CI95%= 0.06, 1.08 p< 0.01). A further mediation analysis showed that PDDR (B= 0.05, CI95%= 0.01, 0.09 p< 0.001), SDM (B= 0.07, CI95%= 0.01, 0.13 p< 0.001) and PDRQ9 (B= 0.08, CI95%= 0.01, 0.16 p< 0.001) significantly mediated the relationship between illness coherence and ITP.

Conclusion: Findings highlighted two key elements: (a) the importance of patient trust in their physician in relation to medication adherence and (b) patients’ good understanding of their illness is linked to a better relationship with their doctor and greater participation in shared-decision making which is associated with increased trust. Tailored psycho-educational interventions could contribute to improving the quality of patient-doctor relationship, increase trust and SDM which, in turn, might improve medication adherence in patients with LN.


Disclosure: S. Georgopoulou, None; L. Nel, None; S. Sangle, None; D. D'Cruz, AstraZeneca, Bristol-Myers Squibb, 2, 5, Eli Lilly, Eli Lily, 2, 5, GlaxoSmithKline, 2, 5, Human Genome Sciences, 5, Idorsia, Merck Serono, 2, 5, Pfizer, Roche, 5, TEVA, 2, 5.

To cite this abstract in AMA style:

Georgopoulou S, Nel L, Sangle S, D'Cruz D. Physician-Patient Interaction and Medication Adherence in Lupus Nephritis [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/physician-patient-interaction-and-medication-adherence-in-lupus-nephritis/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/physician-patient-interaction-and-medication-adherence-in-lupus-nephritis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology